Capastat

Capastat

a trademark for an antibiotic (capreomycin).
Mentioned in ?
References in periodicals archive ?
The Speke site produces the drug Capastat, one of few available to treat multi-drug resistant tuberculosis (MDRTB).
Two Lilly antibiotics, Capastat and Seromycin, are used to fight the super bugs, and the company is making them available to the WHO at discounted prices.
Expansion of its Capastat drug plant will help treat multi-drug resistant tuberculosis, which kills three million people every year, mainly in under-developedcountries.
Successfully launched five new products: Injectable Vancomycin, Capastat and Hydralazine; and Apraclonidine and Ketorolac Ophthalmic in addition to the re-launch of Akten[R].
The Speke plant is currently the sole worldwide source for the drug Capastat, which is a vital antibiotic necessary for multiple drug-resistant tuberculosis treatment.
A newly-completed $7 million expansion of Lilly's manufacturing facility in Speke, an operation south of Liverpool in the United Kingdom, will double the company's capacity for producing Capastat.
Lilly continues to supply both Capastat and Seromycin at discounted prices to WHO Green Light Committee-approved MDR-TB DOTS-Plus programs around the world.
While we continue to look for additional operational efficiencies and cost saving opportunities, we will shift our focus in the second half of 2009 towards increasing the pull-through demand from our hospital clients, increasing direct sales in Ophthalmology and launching three new products: Capastat, Ciprofloxacin and Apraclonidine, as well as implementing new contract manufacturing accounts.
The plant in Speke will produce Capastat,a drug used to treat Multi-Drug Resistant Tuberculosis (MDR-TB).
The Lilly Speke factory is a key part of this initiative and is currently the sole worldwide source for Capastat which is a vital antibiotic necessary for MDR-TB treatment.
Akorn will own the Capastat NDA and expects to launch the product in the third quarter of this year.
Lilly granted to Dura an exclusive license to market Seromycin and Capastat Sulfate, in the $40 million tuberculosis segment of the U.